⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 1, 2024Clinical ophthalmologyOpen Access

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Tsing Hong Wang Tin Aung Da‐Wen Lu Ronnie George Sirisha Senthil Fenghe Lu Noriko Odani‐Kawabata Ki Ho Park

View Full Paper

Ask AI

Bookmark

Share

Abstract

To compare the efficacy and safety of omidenepag isopropyl (OMDI) 0.002% with latanoprost 0.005% once daily in Asian subjects with open-angle glaucoma (OAG)/ocular hypertension (OHT).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e61dfeb6db6435875b032e https://doi.org/10.2147/opth.s465369

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety Comparison of Omidenepag Isopropyl and Latanoprost: A Phase-4 Clinical TrialHuman Clinical Trial · 2026
2Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)2024 · 19 citations
3Omidenepag Isopropyl (Omlonti) for GlaucomaOriginal Research · 2026
4Intraocular pressure lowering effect of Omidenepag Isopropyl in Glaucoma: Comparing between Normal-Tension Glaucoma and Primary Open-Angle Glaucoma2024
5Effects of Topical Omidenepag Isopropyl on Intraocular Pressure and Pupil Diameter in Normal DogsCohort Study · 2026